ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
The Future of ...
ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Clinical trial...
ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Current protoc...
ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Up and coming ...
ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Fax Order Form...
ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Payment Inform...
Upcoming SlideShare
Loading in …5
×

The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus

830 views

Published on

There has been considerable media hype and clinical interest in cancer immunotherapy in recent years. Indeed, there is talk of late stage cancers such as melanoma and NSCLC being managed as chronic conditions with significant increases in life expectancy. There is even speak of a cure.But what is the true state of cancer immunotherapy research' Can we really be sure that the promise of early-stage success will be seen in late-stage clinical trials' Importantly, what do leading clinicians think about the products and research and how do they see things playing out in the clinical setting'Undoubtedly, few research developments in recent years have held such promise to provide a game changing shift in the treatment of cancer. Ever since the launch of Dendreon's Provenge (sipuleucel-T) and, more recently BMS' checkpoint inhibitor Yervoy (ipilimumab), there has been growing knowledge and anticipation that we are on the cusp of a radical new era of cancer management. As one leading KOL puts it "this is nothing less than an explosion in the options for our patients"Opportunities and challengesImmediate research interest is focussed on the CTLA-4L, PD1 and PD-L1 classes, with many expected to market in the medium term in a battle between BMS, Merck, Roche and AZ among others. The PD-1 products have shown high-levels of efficacy in trials leading to hitherto unseen therapeutic outcomes in melanoma and NSCLC with the prospect of wider indications to follow as research advances.But there are challenges too. The expected high costs of therapy will need to be mitigated by the development and use of accurate diagnostic biomarkers - an area still lagging in significant progress. Moreover, current clinical trial protocols are felt to be inappropriate for assessing immunotherapeutics. The disappointing results from Dendreon's Provenge have brought into question the value and role cancer vaccines might play in the treatment mix, though research is ongoing.It is still early days. How immunotherapeutics will be best utilised is still open to question, though application in combination with other agents and treatment regimes seems to yield the best results.The bottom line here is that cancer immunotherapies will revolutionise cancer treatment and the fortunes of the companies who bring effective and safe products to the market.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
830
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus

  1. 1. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus Published on June 2014 Report Summary There has been considerable media hype and clinical interest in cancer immunotherapy in recent years. Indeed, there is talk of late stage cancers such as melanoma and NSCLC being managed as chronic conditions with significant increases in life expectancy. There is even speak of a cure. But what is the true state of cancer immunotherapy research' Can we really be sure that the promise of early-stage success will be seen in late-stage clinical trials' Importantly, what do leading clinicians think about the products and research and how do they see things playing out in the clinical setting' Undoubtedly, few research developments in recent years have held such promise to provide a game changing shift in the treatment of cancer. Ever since the launch of Dendreon's Provenge (sipuleucel-T) and, more recently BMS' checkpoint inhibitor Yervoy (ipilimumab), there has been growing knowledge and anticipation that we are on the cusp of a radical new era of cancer management. As one leading KOL puts it "this is nothing less than an explosion in the options for our patients" Opportunities and challenges Immediate research interest is focussed on the CTLA-4L, PD1 and PD-L1 classes, with many expected to market in the medium term in a battle between BMS, Merck, Roche and AZ among others. The PD-1 products have shown high-levels of efficacy in trials leading to hitherto unseen therapeutic outcomes in melanoma and NSCLC with the prospect of wider indications to follow as research advances. But there are challenges too. The expected high costs of therapy will need to be mitigated by the development and use of accurate diagnostic biomarkers - an area still lagging in significant progress. Moreover, current clinical trial protocols are felt to be inappropriate for assessing immunotherapeutics. The disappointing results from Dendreon's Provenge have brought into question the value and role cancer vaccines might play in the treatment mix, though research is ongoing. It is still early days. How immunotherapeutics will be best utilised is still open to question, though application in combination with other agents and treatment regimes seems to yield the best results. The bottom line here is that cancer immunotherapies will revolutionise cancer treatment and the fortunes of the companies who bring effective and safe products to the market. Table of Content Highlights There are several types of cancer immunotherapy, but checkpoint inhibitors are showing the most promise There is a focus on melanoma and lung cancer for immunotherapy R&D The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus (From Slideshare) Page 1/6
  2. 2. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Clinical trial design will have to be adapted in order for cancer immunotherapies to fully demonstrate their potential in this setting Combinations of immunotherapies are the most promising and appealing approach for oncologists Cancer immunotherapies: hype or reality' Research objectives and methodology Setting the scene: what is cancer immunotherapy' Definitions and history History to the present day Recent developments have seen cancer immunotherapy advance significantly The launch of Yervoy signalled a new era for cancer immunotherapy Is the excitement around cancer immunotherapy justified' Lung cancer is a key area of focus for immunotherapeutic development Today's advances in the development and commercialisation of cancer immunotherapies are just the 'tip of the iceberg' Cancer immunotherapy: tumour-immune system interaction, key immunotherapy technologies and mechanisms of action Tumours, the immune system and their interaction with immunotherapy Key immunotherapy technologies Mechanisms of action of leading cancer immunotherapies Interleukin-2 (IL-2) and interferon-alpha (IFN- ') Checkpoint inhibitors CTLA-4 inhibitors Therapeutic cancer vaccines Chimeric antigen receptor (CAR) therapy Clinical data summary for key cancer immunotherapies Key data for Yervoy (ipilimumab; Bristol-Myers Squibb) Melanoma Yervoy in lung cancer Key data for nivolumab (BMS-936558; BMS) Metastatic melanoma NSCLC Renal cell carcinoma Key data for MPDL3280A (Roche) Phase I Study of MPDL3280A (Roche) in patients with Locally Advanced or Metastatic Solid Tumours (NCT01375842) A Phase I study in metastatic urothelial bladder cancer Pembrolizumab (MK-3575, Merck & Co.) Advanced melanoma NSCLC Phase I study results of pembrolizumab (MK-3475) in NSCLC PD-L1 as a predictor or marker of response to pembrolizumab Key data for MEDI4736 (AstraZeneca) How cancer immunotherapies potentially fit into current treatment paradigms Advanced melanoma The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus (From Slideshare) Page 2/6
  3. 3. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Current protocol Potential role of immunotherapy in the protocol for melanoma Checkpoint inhibitors in BRAF mutation tumours Protocol for other cancers Lung cancer Key issues in the clinical development and design of cancer immunotherapies and their trials Clinical development endpoints specific to immunotherapy trials Immune response criteria Landmark Endpoints Indications: single or multiple tumour types' Combinations of cancer therapies incorporating immunotherapies Combining different mechanisms of action Chemotherapy plus immunotherapy Big opportunities with combinations Practical issues with combination trials Which patients will benefit and from which combinations' Combinations: administer in parallel or sequentially' Biomarkers Key biomarkers in relation to immunotherapy Defining the population for immunotherapy: PD-L1 How reliable are investigational biomarkers' Biomarkers in NSCLC Other biomarkers Payer attitudes toward biomarkers Critical success factors for commercial uptake of cancer immunotherapies Education and marketing Educating the patient Educating the clinician Having a rich and diverse pipeline Cost and reimbursement Duration of treatment Cost as a function of efficacy and survival Market expansion Influence of the oncology community Analysis and comparison of key late-stage checkpoint inhibitors CTLA-4, PD-1 or PD-L1' Drug profiles including summary of key data on efficacy, toxicity, and indications Comparison of checkpoint inhibitor data both with other checkpoint inhibitors and other forms of cancer therapy Future for cancer immunotherapies: looking ahead to 2020 and beyond Data to watch Different cancer types, different contexts and combinations Immuno-responsive tumours The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus (From Slideshare) Page 3/6
  4. 4. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Up and coming checkpoint targets Future of cancer immunotherapy in lung cancer Endpoints over the next 5 years Ultimately, what do the experts want and expect to see cancer immunotherapies deliver' Conclusion KOL panel Appendix Table 8: Summary of clinical trials with ipilimumab in melanoma, June 2014 Table 9: Summary of ongoing clinical trials with ipilimumab in NSCLC, June 2014 Table 10: Summary of ongoing clinical trials with nivolumab, June 2014 Table 11: Summary of ongoing clinical trials with MPDL3280A, June 2014 Table 12: Summary of key ongoing clinical trials with pembrolizumab (MK-3475), June 2014 The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus (From Slideshare) Page 4/6
  5. 5. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Product Formats Please select the product formats and the quantity you require. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________ The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus 1 User License--USD 4 995.00 Quantity: _____ Site License--USD 9 990.00 Quantity: _____ Corporate License--USD 14 985.00 Quantity: _____ The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus (From Slideshare) Page 5/6
  6. 6. ReportLinker Find Industry reports, Company profiles and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 Customer signature:   The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus (From Slideshare) Page 6/6

×